Dr Mohamed Bouattour, Onco-hepatology (hepatocellular carcinoma, cholangiocarcinoma, rare liver cancers)

Specialty

Onco-hepatology (hepatocellular carcinoma, cholangiocarcinoma, rare liver cancers)

Hospital

Hôpital Beaujon (Clichy)

Latest articles

Second-Line TKI after First-Line Immunotherapy-based Treatment in Advanced HCC: Reconstructed IPD Meta-analysis. (May 12, 2026)
Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer). (May 1, 2026)
Vessels Encapsulating Tumor Clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab. (Apr 29, 2026)
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data. (Apr 20, 2026)
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma. (Feb 19, 2026)